Evidence map›Paper›PMID 27335998›Full record

ArticleGlobal pediatric health2016

Validation of Cefazolin as Initial Antibiotic for First Upper Urinary Tract Infection in Children.

Yoshifusa Abe, Hitomi Wakabayashi, Yasuha Ogawa, Ayano Machida, Mio Endo, Tetsuro Tamai, Shunsuke Sakurai, Satoshi Hibino, Takeshi Mikawa, Yoshitaka Watanabe and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global pediatric health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. β-Lactams and β-Lactamase Inhibitors: An Overview.Cold Spring Harbor perspectives in medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yoshifusa AbeShowa University, Tokyo, Japan.
Hitomi WakabayashiShowa University, Tokyo, Japan.
Yasuha OgawaShowa University, Tokyo, Japan.
Ayano MachidaShowa University, Tokyo, Japan.
Mio EndoShowa University, Tokyo, Japan.
Tetsuro TamaiShowa University, Tokyo, Japan.
Shunsuke SakuraiShowa University, Tokyo, Japan.
Satoshi HibinoShowa University, Tokyo, Japan.
Takeshi MikawaShowa University, Tokyo, Japan.
Yoshitaka WatanabeShowa University, Tokyo, Japan.
Kazuhisa UgajinShowa University, Tokyo, Japan.
Kunihiko FukuchiShowa University, Tokyo, Japan.
Kazuo ItabashiShowa University, Tokyo, Japan.
Showa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To validate the policy of administering cefazolin (CEZ) as a first-line antibiotic to children who are hospitalized with their first febrile urinary tract infection (UTI), we evaluated microbial susceptibility to CEZ and the efficacy of CEZ. The 75 enrolled children with febrile UTI were initially treated with CEZ. Switching CEZ was not required in 84% of the patients. The median fever duration, prevalence of bacteremia, prevalence of UTI caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, and median duration of hospitalization were significantly higher in the CEZ-ineffective group. The risks of vesicoureteral reflux, indication of operation, and renal scarring are not increased, even when CEZ is ineffective as a first-line antibiotic. CEZ is effective in more than 80% of pediatric patients with their first febrile UTI, but it should be switched to appropriate antibiotics considering sepsis or the ESBL-producing Enterobacteriaceae pathogen, when fever does not improve within 72 hours.

Indexed as

antibioticscefazolinchildrenupper urinary tract infectionvalidation

Identifiers

PMID27335998
PMCPMC4784558
OpenAlexW2360153515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.